NT 10-Q 1 bglc_nt10q.htm NT 10-Q bglc_nt10q.htm




Washington, D.C. 20549


FORM 12b-25


Notification Of Late Filing

SEC File Number 333-201360


☐ Form 10-K     ☐  Form 20-F     ☐ Form 11-K  ☒ Form 10-Q     ☐  Form 10-D     ☐ Form N-SAR     ☐  Form N-CSR


For Period Ended: June 30, 2023




Full Name of Registrant: BioNexus Gene Lab Corp.


Address of Principal Executive Office:


Unit 02, Level 10 Tower B, Avenue 3, The Vertical

Business Suite II Bangsar South No. 8 Jalan Kerinchi

Kuala Lumpur, Malaysia





PART II: RULES 12b-25(b) AND (c)


If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b- 25(b), the following should be completed. (Check box if appropriate)



The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense




The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and




The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.




BioNexus Gene Lab Corp. (the “Registrant”) was unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q for the three months ended June 30, 2023 (the “Quarterly Report”) by June 30, 2023 filing date applicable to smaller reporting companies due to a delay experienced by the Registrant in completing its financial statements and other disclosures in the Quarterly Report. As a result, the Registrant is still in the process of compiling the required information to complete the Quarterly Report, and its independent registered public accounting firm requires additional time to complete its review of the financial statements for the three months ended June 30, 2023, to be incorporated in the Quarterly Report. The Registrant anticipates that it will file the Quarterly Report no later than the fifth calendar day following the prescribed filing date.





Name and telephone number of person(s) to contact in regard to this notification



Sook Keng Yeoh








Area Code


Telephone Number



Have all other periodic reports required under section 13 or 15(d) of the Securities Exchange Act of 1934 or section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the Registrant was required to file such report(s) been filed? If the answer is no, identify report(s).




YES ☒     NO ☐



Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?



YES ☐     NO ☒




If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.






BioNexus Gene Lab Corp. has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.




BioNexus Gene Lab Corp.






Dated: August 14, 2023


/s/ Sook Keng Yeoh




Sook Keng Yeoh




Chief Executive Officer